SUBCLINICAL MESOTHELIOMA
Clinical trials for SUBCLINICAL MESOTHELIOMA explained in plain language.
Never miss a new study
Get alerted when new SUBCLINICAL MESOTHELIOMA trials appear
Sign up with your email to follow new studies for SUBCLINICAL MESOTHELIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Withdrawn trial aimed to halt rare cancer in High-Risk families
Disease control TerminatedThis study aimed to test if an oral drug called APG-115 could stop or slow the growth of early-stage mesothelioma in people with a specific inherited gene mutation (BAP1). Participants would have taken the drug at home in repeating cycles while undergoing regular scans and biopsi…
Matched conditions: SUBCLINICAL MESOTHELIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC
-
Pill aims to halt early cancer in High-Risk patients
Disease control TerminatedThis study is testing whether an oral drug called INQOVI can stop or improve very early-stage mesothelioma in people born with a specific gene mutation (BAP1) that makes them highly likely to develop this cancer. Participants take the pill for six months while doctors closely mon…
Matched conditions: SUBCLINICAL MESOTHELIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 16, 2026 15:25 UTC